Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05881993 · ClinicalTrials.gov registry record · Early Phase 1
Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects
A Early Phase 1 study of Healthy Volunteer Study, sponsored by Comanche Biopharma.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT05881993: Completed Early Phase 1 study of Healthy Volunteer Study, sponsored by Comanche Biopharma.
NCT05881993 is a Early Phase 1 study of Healthy Volunteer Study that has completed, run by Comanche Biopharma. The registered enrollment target is 45 participants, above the 31-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05881993, a Early Phase 1 study of Healthy Volunteer Study, has completed, sponsored by Comanche Biopharma.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.
Primary Outcome
Number of participants with treatment-related adverse events
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CBP-4888
Study Locations (1)
Texas
- Comanche Biopharma Clinical Research Site #1 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2024-05-22 |
| Phase | Early Phase 1 |
What the finished NCT05881993 record still lists
NCT05881993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, above the 31-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Healthy Volunteer Study appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05881993 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05881993 about?
NCT05881993 is a clinical study titled "Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects". This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.
What is the current status of trial NCT05881993?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 45 participants. The study started on 2023-05-22. Estimated completion is 2024-05-22.
What conditions does trial NCT05881993 study?
This clinical trial studies the following conditions: Healthy Volunteer Study.
What interventions are being tested in trial NCT05881993?
The interventions under investigation include: Placebo (OTHER), CBP-4888 (DRUG).
Who is sponsoring clinical trial NCT05881993?
This trial is sponsored by Comanche Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05881993 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer Study
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05881993's enrollment target sits among peer trials
45 3rd of 9 higher than 7 of 9 other Healthy Volunteer Study trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteer Study trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response
RECRUITING · Early Phase 1
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
RECRUITING · Phase 1
-
Near-InfraRed Spectroscopy of Auricular Stimulation
RECRUITING · NA
-
A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects
COMPLETED · Phase 1
-
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI